Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metasta - HER2 Support Group Forums

		HER2 Support Group Forums > General Cancer News
Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metasta

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply

06-07-2010, 03:59 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,951	Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metasta Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients. More...

Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 06:13 PM.

free webpage hit counter